Royal Marsden Nhs Foundation Trust

This study tested a combination of two drugs, crizotinib and fulvestrant, in 33 people with advanced lobular breast cancer or other cancers linked to a CDH1 gene mutation. The goal was to see if the treatment could shrink tumors and to check for side effects. While both drugs had…

This study tested a precise type of radiation (SBRT) in 86 men with prostate cancer that had started growing despite hormone therapy. The goal was to see if zapping just the growing spots could slow the cancer down and delay the need for chemotherapy. The researchers also looked …

This early-phase study tested a combination of two drugs—pembrolizumab (an immunotherapy) and gemcitabine (a chemotherapy)—in 25 people with rare soft tissue sarcomas (leiomyosarcoma or undifferentiated pleomorphic sarcoma) that had spread or couldn't be removed. The main goal wa…

This early-phase trial tested whether adding the drug avelumab (compound 451238) to radiation therapy is safe for people with advanced soft-tissue sarcoma that has spread. Twelve adults with at least two tumors not curable by standard treatments took part. The main goal was to ch…

This early-phase study tested whether combining the immunotherapy drug pembrolizumab with standard palliative radiotherapy is safe for people with advanced lung cancer. Twenty-four participants received different doses of pembrolizumab alongside radiation, then continued pembroli…

This study looked at 388 women with advanced ovarian, fallopian tube, or peritoneal cancer who were taking the drug niraparib as ongoing maintenance treatment. Researchers tracked side effects and treatment patterns in routine UK clinics, without giving any new treatment. The goa…